A Single and Multiple Ascending Dose Trial of LT-002-158 in Healthy Adult Volunteers

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
LT-002-158 is an oral IRAK4 protein degrader being developed for the treatment of autoimmune disease and inflammation including Hidradenitis Suppurativa and Atopic Dermatitis. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of LT-002-158 in healthy volunteers. The effects of food on the pharmacokinetics of LT-002-158 will also be assessed in healthy volunteers.
Epistemonikos ID: ec81c93719c06ecd0f445524363b47bcc6ac2c9c
First added on: May 15, 2024